• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
High Quality Yeast Beta Glucan for Health & Beauty Applications
Carfilzomib
Ibuprofen Arginine
Uridine 5’-triphosphate trisodium salt（UTP-Na3）
Uridine 5’-diphosphate disodium salt（UDP-Na2）
Semaglutide

NATCO launches Rivaroxaban¸ anticoagulant medication in India

expresspharmaDecember 18, 2020

Tag: NATCO , India , Rivaroxaban

Natco Pharma announced the launch of Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots. Rivaroxaban is currently sold by Bayer under the brand name of Xarelto, in the Indian market.

“After successful previous launches of DABIGAT (Dabigatran) and APIGAT (Apixaban) by NATCO, this latest Rivaroxaban NOAC (novel oral anti-coagulant) is in line with our company’s mission of affordable medicines accessible to all,” informed a company release.

NATCO has launched RPIGAT in four strengths- 20 mg, 15 mg, 10 mg and 2.5 mg. The 20 mg strength is priced at an MRP of Rs 14.0 per tablet.

Previous:Chlorhexidine mouthwash can kill novel coronavirus: Study

Next:Novartis to acquire Cadent Therapeutics for $770 mn

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

NATCO launches Rivaroxaban¸ anticoagulant medication in India | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Rivaroxaban

Rivaroxaban
Rivaroxaban Impurity H

Rivaroxaban Impurity H
Rivaroxaban

Rivaroxaban
Rivaroxaban

Rivaroxaban
Rivaroxaban Impurity T

Rivaroxaban Impurity T
Rivaroxaban

Rivaroxaban
Rivaroxaban

Rivaroxaban
Rivaroxaban

Rivaroxaban
Rivaroxaban

Rivaroxaban
Rivaroxaban

Rivaroxaban

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service